Sanofi-Aventis and Lilly in Cialis marketing pact

Share this article:
Sanofi-Aventis has teamed with Eli Lilly in a collaboration to market erectile-dysfunction drug Cialis (tadalafil) to US urologists. 

According to Lilly spokesperson Lee Lang, the campaign hopes to “educate urologists nationwide by providing direct selling support for 2.5 mg and 5 mg doses, as well as for use on an ‘as needed' basis.” Lang explains the decision, noting Sanofi's “strong market position in urology.”
Sanofi-Aventis spokeswoman Noelle Boyd added, “Our sales force has developed trust among urologists over the years.” Sanofi-Aventis markets Uroxatral (alfuzosin HCI), for benign prostatic hyperplasia (BPH), and Taxotere (docetaxel), a chemotherapy indicated for prostate cancer, to urologists.

The partnership follows FDA approval in January for a once-daily use in 2.5 mg and 5 mg doses.  Cialis is also known as the “36 hour pill” or the “weekend pill,” due to its longer duration of action in patients. 

A spokesperson for Lilly told CNNMoney that the collaboration with Sanofi-Aventis began on March 13.  On the consumer side, Cialis was recently ranked second in the Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests, according to a Manhattan Research study. 
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.